A study looking into technology’s role in cancer patient management is set to be conducted at the Haga Teaching Hospital in the Netherlands. The researchers will be using VitalPatch, a product created by Vital Connect that can detect 8 vital signs including heart rate, respiratory rate, skin temperature, posture, activity, patient falling, and provides ECG monitoring. Vital Connect has teamed up with physIQ for this study to utilize their product pinpointIQ, the only FDA approved analytics software to detect subtle deviations in vitals from the patients baseline data. Just last year, physIQ received $8 million in series B funding, bringing the companies value up to $19.9 million.
Patients in the study will wear the VitalPatch continuously, with their physiological information being captured with pinpointIQ. The patients will either be treated via erythrocyte transfusion or chemotherapy, with some patients going through immunotherapy. Researchers will give them the patch prior to treatment, allowing the pinpointIQ AI to set baseline readings for each patient. From the VitalPatch’s readings given during and after treatment, researchers will analyze how patients respond throughout stages of each treatment. Financed by Janssen Pharmaceuticals, this study will hopefully provide data that assists physicians in properly handling complications associated with treatment.
“By monitoring patients this way, we hope to identify a novel approach to proactively identifying and managing adverse events that may otherwise negatively impact patient outcomes,” says Dr. Martin Schipperus, hematologist at Haga Teaching Hospital.
Vital Connect technology has been researched in previous studies as well, with their HealthPatch MD being found to identify hypoglycemic events in diabetics via heart rate in a study conducted this March. The VitalPatch and pinpointIQ have both already been used by multiple health care providers and hospitals as well.
Both companies have also begun collaborating on an initiative involving home patient care, with the goal of reducing hospitalizations for common medical issues. The first phase of this study began in September of 2016 and involved 30 patients receiving traditional hospital care and 30 receiving home treatment utilizing VitalPatch and physIQ software. The companies plan to expand cohort size in similar studies to compare the efficacy of their technology to in-hospital care.